SWITCH: Apixaban vs Vitamin K in HM3
NCT07471139
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This study is being done to learn the safety and efficacy of a new anticoagulant therapy with apixaban as compared to warfarin to prevent thrombotic events while protecting from bleeding complications in patients with advanced heart failure who are chronically supported by a HeartMate 3 Left Ventricular Assist Device for 3 months.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- LVAD (Left Ventricular Assist Device) Thrombosis
- Heart Failure
- Bleeding
- Thrombosis; Artery
- Stroke
- Heart Transplant
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Columbia University
- Last updated on ClinicalTrials.gov
- November 4, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
New York · 1
- Columbia University Irving Medical Center · New York, NY
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.